Trend Following
(11)
▼
Momentum
(6)
▼
Volatility
(5)
▼
Pattern Recognition
(5)
▼
Mean Reversion
(4)
▼
Volume Based
(5)
▼
Advanced
(10)
▼
BRNS
$0.6379
$
Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in developing novel T cell immunotherapeutics to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. It is advancing a pipeline of product candidates across a range of therapeutic areas, including VTP-300, an immunotherapeutic candidate designed as a potential component of a functional cure for chronic HBV infection; VTP-200, a non-surgical product candidate for persistent high-risk human papillomavirus (HPV); VTP-1000, an autoimmune candidate designed to utilize the SNAP-TI platform to treat patients with celiac disease; VTP-850, a second-generation immunotherapeutic candidate designed to treat recurrent prostate cancer; and VTP-1100, a preclinical cancer candidate designed to utilize the SNAP-CI platform to treat patients with HPV-related cancer. The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023. Barinthus Biotherapeutics plc was founded in 2016 and is headquartered in Harwell, the United Kingdom.
Next Earnings
2026-02-25
Beta
-0.65
Average Volume
Market Cap
Last Dividend
CIK
0001828185
ISIN
US91864C1071
CUSIP
CEO
William J. Enright
Sector
Healthcare
Industry
Biotechnology
Full Time Employees
105
IPO Date
2021-04-30
Status
Active
Latest News
| Title | Headline | Publisher | Date |
|---|---|---|---|
| Short Interest in Barinthus Biotherapeutics PLC Sponsored ADR (NASDAQ:BRNS) Grows By 72.8% | Barinthus Biotherapeutics PLC Sponsored ADR (NASDAQ: BRNS - Get Free Report) saw a large increase in short interest in the month of December. As of December 31st, there was short interest totaling 7,478 shares, an increase of 72.8% from the December 15th total of 4,327 shares. Based on an average trading volume of 75,968 shares, the | Defense World | 2026-01-15 04:10:55 |
| Barinthus Biotherapeutics PLC Sponsored ADR (BRNS) Upgraded to Buy: What Does It Mean for the Stock? | Barinthus Biotherapeutics PLC Sponsored ADR (BRNS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). | Zacks Investment Research | 2025-12-15 13:01:09 |
| Contrasting Barinthus Biotherapeutics (NASDAQ:BRNS) & Oncobiologics (NASDAQ:OTLK) | Oncobiologics (NASDAQ: OTLK - Get Free Report) and Barinthus Biotherapeutics (NASDAQ: BRNS - Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, institutional ownership, profitability, earnings and risk. Valuation and Earnings This table compares Oncobiologics and | Defense World | 2025-12-11 02:00:52 |
SEC Filings
| Type | Filing Date | Accepted Date | Link |
|---|---|---|---|
| 425 | 2026-02-23 | 2026-02-23 | View Filing |
| 8-K | 2026-02-23 | 2026-02-23 | View Filing |
| 8-K | 2026-01-06 | 2026-01-06 | View Filing |
| 8-K | 2025-12-10 | 2025-12-10 | View Filing |
| 10-Q | 2025-11-07 | 2025-11-07 | View Filing |
| 8-K | 2025-11-07 | 2025-11-07 | View Filing |
| 425 | 2025-09-30 | 2025-09-30 | View Filing |
| 425 | 2025-09-30 | 2025-09-30 | View Filing |
| 8-K | 2025-09-30 | 2025-09-30 | View Filing |
| 8-K/A | 2025-08-08 | 2025-08-08 | View Filing |
| 10-Q | 2025-08-07 | 2025-08-07 | View Filing |
| 8-K | 2025-08-07 | 2025-08-07 | View Filing |
| 4 | 2025-06-11 | 2025-06-11 | View Filing |
| 4 | 2025-06-11 | 2025-06-11 | View Filing |
| 4 | 2025-06-11 | 2025-06-11 | View Filing |
| 4 | 2025-06-11 | 2025-06-11 | View Filing |
| 4 | 2025-06-11 | 2025-06-11 | View Filing |
| 4 | 2025-06-11 | 2025-06-11 | View Filing |
| 8-K | 2025-06-10 | 2025-06-10 | View Filing |
| 10-Q | 2025-05-07 | 2025-05-07 | View Filing |
| 8-K | 2025-05-07 | 2025-05-07 | View Filing |
| ARS | 2025-04-25 | 2025-04-25 | View Filing |
| DEFA14A | 2025-04-25 | 2025-04-25 | View Filing |
| DEF 14A | 2025-04-25 | 2025-04-25 | View Filing |
| S-8 | 2025-03-20 | 2025-03-20 | View Filing |
| 10-K | 2025-03-20 | 2025-03-20 | View Filing |
| 8-K | 2025-03-20 | 2025-03-20 | View Filing |
| SC 13G/A | 2025-02-11 | 2025-02-11 | View Filing |
| 4 | 2025-02-05 | 2025-02-05 | View Filing |
| 4 | 2025-02-05 | 2025-02-05 | View Filing |
| 4 | 2025-02-05 | 2025-02-05 | View Filing |
| 4 | 2025-02-05 | 2025-02-05 | View Filing |
| 8-K | 2025-01-10 | 2025-01-10 | View Filing |
| 3/A | 2024-12-31 | 2024-12-31 | View Filing |
| 3 | 2024-12-20 | 2024-12-20 | View Filing |
| 8-K | 2024-11-25 | 2024-11-25 | View Filing |
| 8-K | 2024-11-15 | 2024-11-15 | View Filing |
| 10-Q | 2024-11-06 | 2024-11-06 | View Filing |
| 8-K | 2024-11-06 | 2024-11-06 | View Filing |
| SC 13G/A | 2024-11-01 | 2024-11-01 | View Filing |
| SC 13G | 2024-10-15 | 2024-10-15 | View Filing |
| 8-K | 2024-09-05 | 2024-09-05 | View Filing |
| 10-Q | 2024-08-08 | 2024-08-08 | View Filing |
| 8-K | 2024-08-08 | 2024-08-08 | View Filing |
| 4 | 2024-06-18 | 2024-06-18 | View Filing |
| 3 | 2024-06-18 | 2024-06-18 | View Filing |
| 8-K | 2024-06-12 | 2024-06-12 | View Filing |
| 8-K | 2024-06-06 | 2024-06-06 | View Filing |
| 8-K | 2024-05-15 | 2024-05-15 | View Filing |
| 4 | 2024-05-14 | 2024-05-14 | View Filing |
| 4 | 2024-05-14 | 2024-05-14 | View Filing |
| 4 | 2024-05-14 | 2024-05-14 | View Filing |
| 4 | 2024-05-14 | 2024-05-14 | View Filing |
| 4 | 2024-05-14 | 2024-05-14 | View Filing |
| 4 | 2024-05-14 | 2024-05-14 | View Filing |
| 8-K/A | 2024-05-14 | 2024-05-14 | View Filing |
| 10-Q | 2024-05-13 | 2024-05-13 | View Filing |
| 8-K | 2024-05-13 | 2024-05-13 | View Filing |
| 8-K | 2024-04-18 | 2024-04-18 | View Filing |
| ARS | 2024-03-22 | 2024-03-22 | View Filing |
| DEFA14A | 2024-03-22 | 2024-03-22 | View Filing |
| DEF 14A | 2024-03-22 | 2024-03-22 | View Filing |
| S-8 | 2024-03-20 | 2024-03-20 | View Filing |
| 10-K | 2024-03-20 | 2024-03-20 | View Filing |
| 8-K | 2024-03-20 | 2024-03-20 | View Filing |
Algorithm Performance
Upgrade To Premium for Full Access
| Algorithm | Profit/Loss | Profit Factor | # Trades | Sharpe | Sortino | Efficiency |
|---|---|---|---|---|---|---|
| Larry Williams PercentR Strategy | 24.61% | 0.99 | 133 | 0.02 | 0.05 | 45.02 |
| Mean Reversion Strategy | 10.37% | 1 | 370 | 0.01 | 0.03 | 30.78 |
| Williams PercentR Strategy | 3.40% | 1 | 191 | 0.01 | 0.02 | 23.81 |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | x | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxx | x% | x | xxx | x | x | xxxxx |
| xxxxxxxxx | xxxxxx% | xxxx | xxx | xxxxx | x | xxxxx |
| xxxxxxxxx | xxxxxxx% | xxxx | xxx | x | xxxx | xxxxx |
| xxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxx | xxxxxxxx% | x | xx | x | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | x | xxxx | xxxxx |
| xxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | x | x | xxxx |
| xxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | x |
| xxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxx | xxxxxxxx% | x | x | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |